235 related articles for article (PubMed ID: 33399228)
21. Combination regimens and immunologic mechanisms to enhance the efficacy of cemiplimab for cutaneous squamous cell carcinoma.
Hanania HL; Lewis DJ
Expert Rev Anticancer Ther; 2022 Feb; 22(2):237-238. PubMed ID: 34918605
[No Abstract] [Full Text] [Related]
22. Prompt response of advanced cutaneous squamous cell carcinoma to cemiplimab in a kidney transplant patient receiving treatment with everolimus.
Gambichler T; Hessam S; Lüttringhaus T; Boms S
Clin Exp Dermatol; 2022 Mar; 47(3):608-609. PubMed ID: 34767651
[TBL] [Abstract][Full Text] [Related]
23. RF-Cemiplimab: First Drug Approved for the Treatment of Metastatic or Unresectable Cutaneous Squamous Cell Carcinoma.
Morgado-Carrasco D; Bosch-Amate X; Fustà-Novell X; Giavedoni P
Actas Dermosifiliogr (Engl Ed); 2020 Mar; 111(2):161-163. PubMed ID: 31874704
[No Abstract] [Full Text] [Related]
24. Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer.
Song IH; Heo SH; Bang WS; Park HS; Park IA; Kim YA; Park SY; Roh J; Gong G; Lee HJ
Cancer Res Treat; 2017 Apr; 49(2):399-407. PubMed ID: 27488875
[TBL] [Abstract][Full Text] [Related]
25. Tertiary lymphoid organs in the inflammatory myopathy associated with PD-1 inhibitors.
Matsubara S; Seki M; Suzuki S; Komori T; Takamori M
J Immunother Cancer; 2019 Sep; 7(1):256. PubMed ID: 31533865
[TBL] [Abstract][Full Text] [Related]
26. Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas.
Maubec E; Boubaya M; Petrow P; Beylot-Barry M; Basset-Seguin N; Deschamps L; Grob JJ; Dréno B; Scheer-Senyarich I; Bloch-Queyrat C; Leccia MT; Stefan A; Saiag P; Grange F; Meyer N; de Quatrebarbes J; Dinulescu M; Legoupil D; Machet L; Dereure O; Zehou O; Montaudié H; Wierzbicka-Hainaut E; Le Corre Y; Mansard S; Guégan S; Arnault JP; Dalac S; Aubin F; Alloux C; Lopez I; Cherbal S; Tibi A; Lévy V;
J Clin Oncol; 2020 Sep; 38(26):3051-3061. PubMed ID: 32730186
[TBL] [Abstract][Full Text] [Related]
27. Anti PD-1 Checkpoint Inhibitor As a First-Line Treatment for Advanced Cutaneous Squamous Cell Carcinoma.
Bopota K; Donnelly O; Borumandi F
J Craniofac Surg; 2023 May; 34(3):e247-e249. PubMed ID: 36441840
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation.
Morsch R; Rose M; Maurer A; Cassataro MA; Braunschweig T; Knüchel R; Vögeli TA; Ecke T; Eckstein M; Weyerer V; Esposito I; Ackermann M; Niegisch G; Gaisa NT;
BMC Cancer; 2020 Mar; 20(1):230. PubMed ID: 32188412
[TBL] [Abstract][Full Text] [Related]
29. Cemiplimab-induced cytokine-release syndrome: second case reported and review of the literature.
Lhuillier M; Brière M; Artifoni M; Chapal M; Peuvrel L; Saint-Jean M
Immunotherapy; 2023 Mar; 15(4):229-234. PubMed ID: 36789558
[TBL] [Abstract][Full Text] [Related]
30. Cutaneous lymphoid hyperplasia and cutaneous marginal zone lymphoma: comparison of morphologic and immunophenotypic features.
Baldassano MF; Bailey EM; Ferry JA; Harris NL; Duncan LM
Am J Surg Pathol; 1999 Jan; 23(1):88-96. PubMed ID: 9888708
[TBL] [Abstract][Full Text] [Related]
31. Immune Checkpoint Inhibitors for Treating Advanced Cutaneous Squamous Cell Carcinoma.
Patel R; Chang ALS
Am J Clin Dermatol; 2019 Aug; 20(4):477-482. PubMed ID: 30737731
[TBL] [Abstract][Full Text] [Related]
32. Tertiary lymphoid structures: Associated multiple immune cells and analysis their formation in hepatocellular carcinoma.
Nie Y; Fan H; Li J; Lei X; Zhang T; Wang Y; Mao Z; Tao K; Song W
FASEB J; 2022 Nov; 36(11):e22586. PubMed ID: 36190431
[TBL] [Abstract][Full Text] [Related]
33. Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma.
Ahmed SR; Petersen E; Patel R; Migden MR
Expert Rev Clin Pharmacol; 2019 Oct; 12(10):947-951. PubMed ID: 31524530
[No Abstract] [Full Text] [Related]
34. Early discontinuation of cemiplimab in patients with advanced cutaneous squamous cell carcinoma.
Boutros A; Croce E; Tanda ET; Cecchi F; Arecco L; Genova C; Baldelli I; Lambertini M; Raposio E; Del Mastro L; Spagnolo F
J Geriatr Oncol; 2024 Mar; 15(2):101640. PubMed ID: 37798175
[No Abstract] [Full Text] [Related]
35. PD-1, S-100 and CD1a expression in pseudolymphomatous folliculitis, primary cutaneous marginal zone B-cell lymphoma (MALT lymphoma) and cutaneous lymphoid hyperplasia.
Goyal A; Moore JB; Gimbel D; Carter JB; Kroshinsky D; Ferry JA; Harris NL; Duncan LM
J Cutan Pathol; 2015 Jan; 42(1):6-15. PubMed ID: 25384543
[TBL] [Abstract][Full Text] [Related]
36. Tertiary lymphoid structures, a historical reappraisal.
Ribatti D
Tissue Cell; 2024 Feb; 86():102288. PubMed ID: 38101028
[TBL] [Abstract][Full Text] [Related]
37. Density and maturity of peritumoral tertiary lymphoid structures in oesophageal squamous cell carcinoma predicts patient survival and response to immune checkpoint inhibitors.
Hayashi Y; Makino T; Sato E; Ohshima K; Nogi Y; Kanemura T; Honma K; Yamashita K; Saito T; Tanaka K; Yamamoto K; Takahashi T; Kurokawa Y; Miyata H; Nakajima K; Wada H; Morii E; Eguchi H; Doki Y
Br J Cancer; 2023 Jun; 128(12):2175-2185. PubMed ID: 37016103
[TBL] [Abstract][Full Text] [Related]
38. Cemiplimab removed from reimbursable drugs in France.
Pham F; Reynaud B; Favier B; Darnis S; Amini-Adle M
Eur J Cancer; 2021 May; 149():11-13. PubMed ID: 33812142
[No Abstract] [Full Text] [Related]
39. Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort.
Moreno V; Garrido P; Papadopoulos KP; De Miguel Luken MJ; Gil-Martin M; Aljumaily R; Rosen LS; Rietschel P; Mohan KK; Yoo SY; Stankevich E; Lowy I; Fury MG
Lung Cancer; 2021 May; 155():151-155. PubMed ID: 33831732
[TBL] [Abstract][Full Text] [Related]
40. Squamous differentiation is a potential biomarker predicting tumor progression in patients treated with pembrolizumab for urothelial carcinoma.
Miyama Y; Morikawa T; Miyakawa J; Koyama Y; Kawai T; Kume H; Ushiku T
Pathol Res Pract; 2021 Mar; 219():153364. PubMed ID: 33610951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
